Boselli Francesco, Scarinci Fabio, Fasciani Romina
Ophthalmology, ASST Brianza, Vimercate Hospital, Via Santi Cosma e Damiano 10, 20871 Vimercate, Italy.
Ophthalmology, Fondazione Policlinico Universitatio Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy.
J Clin Med. 2025 Sep 19;14(18):6600. doi: 10.3390/jcm14186600.
Corneal re-epithelialization is a critical process following surgical procedures such as photorefractive keratectomy (PRK), phototherapeutic keratectomy (PTK), and corneal UV cross-linking (CXL), as well as cases of corneal abrasion. Delayed epithelial healing can lead to increased discomfort, a higher risk of infection, and suboptimal visual outcomes. This retrospective case series aims to evaluate the efficacy of a novel ophthalmic solution containing cross-linked carboxymethyl cellulose (CX-CMC) and silk proteins in promoting corneal re-epithelialization and improving post-surgical recovery. A total of 15 patients who underwent PRK, PTK, or CXL or who presented with corneal abrasions were included in the study. Along with standard post-surgical treatment, patients received CX-CMC and silk protein-based eye drops (CORDEV, Ophtagon, Rome, Italy) six times a day. Corneal epithelial thickness was assessed using topography at follow-up visits. Corneal re-epithelialization was observed in all subjects within 24 to 48 h post-procedure. The mean corneal epithelial thickness at 48 h was 73.21 µm, which falls within the typical range of a proliferating corneal epithelium. : The CX-CMC and silk protein-based formulation accelerated corneal healing, achieving rapid epithelial recovery. This novel ophthalmic solution offers a promising alternative to conventional post-surgical treatments, potentially improving patient outcomes by reducing healing time, minimising discomfort, and lowering the risk of complications associated with delayed re-epithelialization.
角膜再上皮化是诸如准分子激光角膜切削术（PRK）、光治疗性角膜切削术（PTK）和角膜紫外线交联术（CXL）等外科手术以及角膜擦伤病例后的关键过程。上皮愈合延迟会导致不适感增加、感染风险升高以及视觉效果欠佳。本回顾性病例系列旨在评估一种含有交联羧甲基纤维素（CX-CMC）和丝蛋白的新型眼科溶液在促进角膜再上皮化和改善术后恢复方面的疗效。共有15例接受PRK、PTK或CXL手术或出现角膜擦伤的患者纳入本研究。除标准术后治疗外，患者每天使用六次基于CX-CMC和丝蛋白的眼药水（CORDEV，Ophtagon，罗马，意大利）。在随访时使用地形图评估角膜上皮厚度。在术后24至48小时内，所有受试者均观察到角膜再上皮化。48小时时的平均角膜上皮厚度为73.21 µm，处于增殖期角膜上皮的典型范围内。基于CX-CMC和丝蛋白的制剂加速了角膜愈合，实现了上皮的快速恢复。这种新型眼科溶液为传统术后治疗提供了一种有前景的替代方案，有可能通过缩短愈合时间、减轻不适感并降低与上皮再形成延迟相关的并发症风险来改善患者预后。
